AVR - Anteris Technologies

[galumay]

Yeah well, I agree, better news than expected. I really thought Wayne Paterson had destroyed the business.

Its a glimmer of hope, with their salaries they will still burn through all the cash in under 12 months, so it may just have delayed the inevitable. Probably the best hope is LeMaitre Vascular make an offer to shareholders to mop up the business.

 

[rcm617]

My pick for the comp. Am hoping for a bit of a bounce next month after the long suspension from trading, after those who want to sell get out. Great science but very poor overpaid management. 4c has shown a bit of improvement on the cost front, but biggest hope for this is a takeover.

 

[galumay]

My pick for the comp. Am hoping for a bit of a bounce next month after the long suspension from trading, after those who want to sell get out. Great science but very poor overpaid management. 4c has shown a bit of improvement on the cost front, but biggest hope for this is a takeover.

Yep, in particular Wayne Paterson has destroyed this business, while filling his pockets with every bit of cash he could squeeze out of it.

 

[rcm617]

Looks like the selling has finished and buyers are in charge. Just need a bit of good news now to really get it going.

 

[Purple XS2]

Looks like the selling has finished and buyers are in charge. Just need a bit of good news now to really get it going.

Indeed.
Would be interesting to know who's buying.
Might just be a flash in the pan, or might be some peeps have reason to believe.

I actually don't hold any AHZ per se, it's all in oppies: AHZO (strike $0.08c Dec 2021)

So the next news when- / what- ever, will be interesting.

Regards,
P

 

[galumay]

I reckon its just a flash in the pan, maybe some pumping from HC?

Wayne Paterson has bled this baby dry.

 

[Purple XS2]

Since posting last November, the rise into the 0.08 - 0.09 range has held, and today closed at $0.12.

Well whoopee.

Looking at todays trades ( a million shares, about $110k worth), I did notice that the bigger chunks, of $5k plus were into the buy stack, with smaller transactions coming from the sellers.
Now, these small volumes don't mean any serious buyers are moving in, but it does seem that larger little fish are buying off the smaller little fish.

A few more months of today's action and I'll start feeling cheerful.

Regards,
P

 

[galumay]

A few more months of today's action and I'll start feeling cheerful.

I would need a couple of years of that action - and the departure of Crooked Wayne Paterson, before I approached anything like cheerful!

 

[tinhat]

@galumay, this is not the USA and you are not POTUS. Be careful what you write.

 

[galumay]

LOL! I didn't pick that up until you mentioned it. Perhaps 'corrupt' is less presidential?

 

[Purple XS2]

In a time where surgeons and medical resources of all calibres are dedicated to COVID-19, the Belgian surgeon Bart Meuris has pulled off the impressive feat of implanting Admedus' first in-human 3-D aortic valve:
https://www.asx.com.au/asxpdf/20200327/pdf/44gg2g8svv3s10.pdf
(27th March), the patient concerned at last report was out of hospital (6th April).
So, big news!
if there are more surgeons (and patients!) willing to give it a go, and their confidence is validated, this could be the start of bigness.
'could'

Fingers crossed.

Regards,
P
(holding AHZO oppies. Last AHZ closing price $6.41 - this of course being post 100-to-1 consolidation, so the equivalent of $0.064c as compared to previous SP quoted in this thread)

 

[galumay]

There was an earlier 10-1 consolidation, so the pain is worse for dummies like me that fell for the narrative in the early days, when Forrest was pumping it.

 

[galumay]

Just checked, 10-1 in late 2015, now 100 -1 last month, 1000-1 destruction of shareholder value by CEO Wayne Paterson! My most expensive parcel was $100 per share and my average is about $46 per share - a long way to go before I am in the black!!

EDIT - TBF I think the 2015 consolidation mught have been before WP started wrecking the business!

 

[System]

On May 22nd, 2020, Admedus Limited (AHZ) changed its name and ASX code to Anteris Technologies Limited (AVR).

 

[Purple XS2]

You say Anteris, I say Admedus: let's call the whole thing off ...
You say Allied, I say BioMD, lets call the whole thing off ...(with apologies to Cole Porter).

So, to entertain the weary shareholders, Admedus rebranded itself (again), and its ASX code, this time from Admedus / AHZ to Anteris Technologies / AVR.

Market underwhelmed from June through July, however ...

... from dipping under $3.00, the AVR share price, on very low volumes, has been making baby steps towards some sort of value. (last vertical bar on the RHS is 16,000 shares sold. The 2 high points in the period each 40,000 odd).
Friday 20th close at $4.20.

With a restructuring of the company, I admit it's beyond my forensics to decipher the financial statements, half yearly report ending June 2020 may be enlightening to some ...
https://www.asx.com.au/asxpdf/20200820/pdf/44lq90nlmp0lrc.pdf

... although I gather Anteris has a couple more quarters in it, without the necessity of yet another cap-raise. But we still have the same board and CEO - they are not known for leaving their cap-raises to last quarter of viability.
Put it this way, if Anteris can pull a rabbit out of the hat - and their heart-valve implant project seems to be progressing, then the shareholders will be the first to hear the happy cry: Cap-raise!

I hold AVR (heads), warily and opportunistically.
I hold AVRO options, bottom draw (exp Dec 2021, strike $8.00).

Regards,
P

 

[galumay]

Yup, its a weary journey @Purple XS2. I finally gave up on this dud in my SMSF, I still hold in my personal portfolio. I will probably keep them as a reminder of the hazards of bio techs and the folly of averaging down into rubbish companies with dodgy management. Wayne Paterson's destruction of value, while filling his own pockets is a salient lesson in the dangers these type of managers hold for retail investors.

 

[Garpal Gumnut]

With a restructuring of the company, I admit it's beyond my forensics to decipher the financial statements, half yearly report ending June 2020 may be enlightening to some ...
https://www.asx.com.au/asxpdf/20200820/pdf/44lq90nlmp0lrc.pdf

... although I gather Anteris has a couple more quarters in it, without the necessity of yet another cap-raise.
P

Looking at the results, the auditor and board comments, this outfit has 18 mo. max left before it is totally out of cash without a significant injection or raise of capital.

gg

 

[Purple XS2]

Anteris continues to promote its surgical product in international symposia, and - going by the company's publicity - it's all making a good impression.
But share proce languishes. $3.75 at last close, end November 2020.
No cap raise in recent times, but cash remains low.

So, will there ever be a rabbit out of a hat?
(Sigh). My bottom-drawer oppies and I ($8.00 strike, Dec 2021) can only wish.

 

[Dona Ferentes]

Looking at the results, the auditor and board comments, this outfit has 18 mo. max left before it is totally out of cash without a significant injection or raise of capital.

For this "structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients, [with its] focus .. on investing in and developing next generation technologies with world class partners and acquiring strategic assets to grow product and service offerings", would a mill help?

Highlights
• $1.1M raised in a placement to sophisticated investors at $3.37 per share – 10% discount to the last closing share price
• Provides working capital as Anteris continues to demonstrate superior performance of the DurAVR™, 3D single-piece, aortic valve

DNH, WSI?

 

[Country Lad]

For this "structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients, [with its] focus .. on investing in and developing next generation technologies with world class partners and acquiring strategic assets to grow product and service offerings", would a mill help?

Highlights
• $1.1M raised in a placement to sophisticated investors at $3.37 per share – 10% discount to the last closing share price
• Provides working capital as Anteris continues to demonstrate superior performance of the DurAVR™, 3D single-piece, aortic valve

View attachment 117410

The $mil might help to pay the script writers. The cynic in me puts anything with this much spin in the don't bother draw.